Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 1/20 | 0.40 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.31 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL811488 | 0.85 | DRD1 (0.46) | GABBR2GABBR1CA2DRD1ALOX5 | |
| SCHEMBL21222728 | 0.76 | ALDH1A1 (0.53) | GABBR2GABBR1CA2ALOX5PTGS1 | |
| SCHEMBL7783615 | 0.75 | GABBR2 (0.64) | GABBR2GABBR1ALOX5PTGS1PTGS2 | |
| Bromide SCHEMBL6851320 | 0.72 | CA2 (0.35) | CA2GABRA1GABRB2TDP1ALDH1A1 | |
| SCHEMBL9455625 | 0.72 | GABBR2 (0.43) | GABBR2GABBR1CA2ALOX5PTGS1 | |
| SCHEMBL24272577 | 0.72 | DRD1 (0.33) | GABBR2GABBR1CA2DRD1 | |
| SCHEMBL15580435 | 0.69 | CA2 (0.46) | CA2GABRA1GABRB2TDP1ALDH1A1 | |
| SCHEMBL11122788 | 0.67 | PTGS2 (0.37) | DRD1PTGS2ALDH1A1TSHR | |
| SCHEMBL2692662 | 0.67 | PTGS2 (0.54) | ALOX5PTGS1PTGS2 | |
| SCHEMBL377211 | 0.66 | PDK2 (0.41) | DRD1ALOX5PDK2PDK4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6743923-B2 | A BENZYLIDENE DERIVATIVES USED FOR OSTEOCLAST FORMATION INHIBITION, A NITROGEN MONOXIDE PRODUCTION INHIBITION, AND A TRANSCRIPTION FACTOR NF KAPPA B SUPRESSING AGENT | SHIONOGI & CO., LTD. (JP) | 2004-06-01 | — | — | US | disclosed |
| US-20030125364-A1 | Antirheumatic agent | MATSUMOTO SAICHI (JP) | 2003-07-03 | — | — | US | disclosed |
| US-6525081-B1 | Inhibiting osteoclast formation and nitrogen monoxide production; suppressing transcription factor NF kappa B | SHIONOGI & CO., LTD. (JP) | 2003-02-25 | — | — | US | disclosed |
| EP-1026162-A1 | ANTIRHEUMATIC | SHIONOGI & CO., LTD. (JP) | 2000-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125364-A1 | Antirheumatic agent | IL1A, IL1B, IL17A | GABBR2 2306/4885GABBR1 2546/4885CA2 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.